Enzo Biochem Beheer

Beheer criteriumcontroles 0/4

De CEO Enzo Biochem is Kara Cannon, benoemd in Sep2023, heeft een ambtstermijn van 1.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.22M, bestaande uit 24.4% salaris en 75.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.54% van de aandelen van het bedrijf, ter waarde $ 321.64K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 1.1 jaar.

Belangrijke informatie

Kara Cannon

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	24.4%
Dienstverband CEO	1.2yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	1.1yrs

Recente managementupdates

Recent updates

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13

Analyse CEO-vergoeding

Hoe is Kara Cannon's beloning veranderd ten opzichte van Enzo Biochem's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	-US$10m
Apr 30 2024	n/a	n/a	-US$18m
Jan 31 2024	n/a	n/a	-US$23m
Oct 31 2023	n/a	n/a	-US$25m
Jul 31 2023	US$1m	US$299k	-US$25m
Apr 30 2023	n/a	n/a	-US$27m
Jan 31 2023	n/a	n/a	-US$24m
Oct 31 2022	n/a	n/a	-US$23m
Jul 31 2022	US$769k	US$270k	-US$20m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	US$300k
Oct 31 2021	n/a	n/a	US$5m
Jul 31 2021	US$426k	US$265k	US$8m
Apr 30 2021	n/a	n/a	US$1m
Jan 31 2021	n/a	n/a	-US$11m
Oct 31 2020	n/a	n/a	-US$21m
Jul 31 2020	US$371k	US$220k	-US$29m
Apr 30 2020	n/a	n/a	-US$31m
Jan 31 2020	n/a	n/a	US$2m
Oct 31 2019	n/a	n/a	US$822k
Jul 31 2019	US$379k	US$220k	US$2m
Apr 30 2019	n/a	n/a	US$2m
Jan 31 2019	n/a	n/a	-US$23m
Oct 31 2018	n/a	n/a	-US$16m
Jul 31 2018	US$342k	US$198k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.22M ) Kara } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van Kara is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kara Cannon (55 yo)

1.2yrs

Tenure

US$1,221,793

Compensatie

Ms. Kara Cannon serves as Chief Executive Officer at Enzo Biochem, Inc. from January 31, 2024 and serves as its Director from 2024 and served as its Interim CEO since September 5, 2023 until January 31, 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kara Cannon	CEO & Director	1.2yrs	US$1.22m	0.54% $ 321.6k
Patricia Eckert	Chief Financial Officer	2yrs	US$453.56k	0.038% $ 22.7k
Brian Fisher	General Counsel	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ENZ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kara Cannon	CEO & Director	less than a year	US$1.22m	0.54% $ 321.6k
Steven Pully	Independent Chairperson of the Board	1.1yrs	geen gegevens	0.034% $ 20.7k
Bradley Radoff	Independent Director	2.8yrs	US$195.00k	8.19% $ 4.9m

1.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ENZ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw bestuur.

Enzo Biochem Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Recent updates

New minor risk - Dividend sustainability

Full year 2024 earnings released: US$0.19 loss per share (vs US$0.51 loss in FY 2023)

Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024

High number of new and inexperienced directors

Enzo Biochem: Is This Time Finally Different?

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought US$197k worth of stock

Insider recently bought US$5.0m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Enzo Biochem appoints Patricia Eckert as interim CFO

Full year 2022 earnings released

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought US$264k worth of stock

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Independent Director recently bought US$276k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought US$2.5m worth of stock

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$1.5m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought US$2.5m worth of stock

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

New 90-day high: US$3.25

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees